No connection

Search Results

ABUS vs AMPH

ABUS
Arbutus Biopharma Corporation
BEARISH
Price
$4.53
Market Cap
$872.0M
Sector
Healthcare
AI Confidence
85%
AMPH
Amphastar Pharmaceuticals, Inc.
BEARISH
Price
$18.18
Market Cap
$835.4M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABUS
--
AMPH
8.96
Forward P/E
ABUS
-27.41
AMPH
5.21
P/B Ratio
ABUS
11.38
AMPH
1.05
P/S Ratio
ABUS
61.92
AMPH
1.16
EV/EBITDA
ABUS
-29.91
AMPH
5.44

Profitability

Gross Margin
ABUS
-79.23%
AMPH
49.46%
Operating Margin
ABUS
-727.31%
AMPH
19.45%
Profit Margin
ABUS
-237.88%
AMPH
13.63%
ROE
ABUS
-38.52%
AMPH
12.9%
ROA
ABUS
-14.94%
AMPH
6.37%

Growth

Revenue Growth
ABUS
-33.2%
AMPH
-1.8%
Earnings Growth
ABUS
--
AMPH
-31.0%

Financial Health

Debt/Equity
ABUS
0.05
AMPH
0.83
Current Ratio
ABUS
15.73
AMPH
4.02
Quick Ratio
ABUS
15.52
AMPH
2.8

Dividends

Dividend Yield
ABUS
--
AMPH
--
Payout Ratio
ABUS
0.0%
AMPH
0.0%

AI Verdict

ABUS BEARISH

ABUS exhibits severe financial distress signals with a Piotroski F-Score of 0/9, indicating extreme weakness in operational and financial health. The company reports massive negative margins, declining revenue, and unprofitable operations, with no meaningful cash flow or profitability. While the low debt-to-equity ratio and high current ratios suggest strong liquidity, they are likely inflated by non-operational cash reserves. The absence of a Graham Number and intrinsic value estimate reflects a lack of sustainable earnings, and the stock trades at a premium valuation despite deteriorating fundamentals. Analysts offer no consensus, and insider activity is neutral, reinforcing a lack of confidence.

Strengths
High current and quick ratios (15.73 and 15.52) indicate strong short-term liquidity
Low debt-to-equity ratio (0.05) suggests minimal leverage risk
Recent 1-year return of +34.4% shows strong price momentum despite fundamentals
Risks
Piotroski F-Score of 0/9 signals severe financial distress and operational failure
Negative profit margins (up to -237.88%) and declining revenue (-33.20% YoY) indicate deteriorating business model
No operating cash flow or free cash flow data available, raising concerns about sustainability
AMPH BEARISH

AMPH exhibits strong deterministic health with a Piotroski F-Score of 7/9, indicating solid operational efficiency and financial stability, though the absence of an Altman Z-Score raises concern about default risk. The stock trades at a discount to its Graham Number ($28.09) and intrinsic value ($14.21), suggesting undervaluation on a defensive basis. However, this is overshadowed by deteriorating fundamentals: negative revenue and earnings growth (YoY -1.8% and -31.0%), declining quarterly earnings, and a significant 36.4% drop in price over the past month. Insider selling activity further undermines confidence, with $0.95M in sales over six months despite no buy activity.

Strengths
Piotroski F-Score of 7/9 indicates strong financial health and operational efficiency
Graham Number of $28.09 suggests defensive undervaluation relative to intrinsic safety margin
High gross margin (49.46%) and operating margin (19.45%) reflect strong pricing power and cost control
Risks
Negative year-over-year earnings growth (-31.0%) and revenue decline (-1.8%) indicate deteriorating business momentum
Recent insider selling of $0.95M over six months signals potential lack of confidence from management
Stock has declined 36.4% in one month and 51.1% over three years, reflecting prolonged underperformance

Compare Another Pair

ABUS vs AMPH: Head-to-Head Comparison

This page compares Arbutus Biopharma Corporation (ABUS) and Amphastar Pharmaceuticals, Inc. (AMPH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile